You are here: Welcome to the MPKB » Welcome to the MPKB » Science behind Marshall Paradigm » Science behind olmesartan (Benicar)
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:protocol:olmesartan [06.01.2019] – [Related publications and presentations] sallieqhome:protocol:olmesartan [03.30.2020] – [Cardiovascular disease] sallieq
Line 1: Line 1:
    
 ====== Science behind olmesartan (Benicar)     ====== ====== Science behind olmesartan (Benicar)     ======
 +
 +
 +<relatedarticle> [[home:food:aim_health:aging|Health maintenance and Olmesartan]] </article>
  
 Patients on the [[home:protocol|Marshall Protocol]] (MP) take olmesartan (Benicar), a drug whose actions are well known, [[home:mp:olmesartan:dosing|every six hours]].  In general, olmesartan tends to be prescribed for its antihypertensive properties due to the fact that is an angiotensin receptor blocker. A growing body of research supports the use of olmesartan as a part of a curative therapy for chronic disease.  Patients on the [[home:protocol|Marshall Protocol]] (MP) take olmesartan (Benicar), a drug whose actions are well known, [[home:mp:olmesartan:dosing|every six hours]].  In general, olmesartan tends to be prescribed for its antihypertensive properties due to the fact that is an angiotensin receptor blocker. A growing body of research supports the use of olmesartan as a part of a curative therapy for chronic disease. 
Line 134: Line 137:
  
 ==== Cardiovascular disease ==== ==== Cardiovascular disease ====
 +
  
 <blockquote>Several prospective, randomized studies show vascular benefits with olmesartan medoxomil: reduced progression of coronary atherosclerosis in patients with stable angina pectoris (OLIVUS); decreased vascular inflammatory markers in patients with hypertension and micro- (pre-clinical) inflammation (EUTOPIA); improved common carotid intima-media thickness and plaque volume in patients with diagnosed atherosclerosis (MORE); and resistance vessel remodeling in patients with stage 1 hypertension (VIOS). <blockquote>Several prospective, randomized studies show vascular benefits with olmesartan medoxomil: reduced progression of coronary atherosclerosis in patients with stable angina pectoris (OLIVUS); decreased vascular inflammatory markers in patients with hypertension and micro- (pre-clinical) inflammation (EUTOPIA); improved common carotid intima-media thickness and plaque volume in patients with diagnosed atherosclerosis (MORE); and resistance vessel remodeling in patients with stage 1 hypertension (VIOS).
home/protocol/olmesartan.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.